| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 15, 2007
Accepted on May 17, 2007
Department of Surgery, University of Pisa, Pisa-Italy (RG, CU, CL, AP, PB, GM, PM, FB). Department of Endocrinology, University of Pisa, Italy (RE). Dipartimento di Biologia e Patologia Cellulare e Molecolare, University ‘Federico II’, c/o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Naples, Italy (GS, MS)
* To whom correspondence should be addressed. E-mail: f.basolo{at}med.unipi.it.
Context. Papillary thyroid carcinoma (PTC) is frequently multifocal. Independent PTC foci may either arise from intraglandular metastases from a single dominant tumor or as unrelated neoplastic clones. In rare cases, the simultaneous presence of PTC foci of different histopathological subtypes points to independent sites of tumor formation.
Objective. We examined the pattern of BRAF mutations in noncontiguous tumor foci and node metastases from 69 patients affected by multicentric PTC. These included 19 cases characterized by the simultaneous presence of different PTC histopathological variants.
Design. BRAF (exon 15) mutation was examined by polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) followed by DNA sequencing in laser-capture microdissected tissue samples.
Results. Discordant patterns of BRAF mutation were found in about 40% of the multifocal PTC. In node metastases, BRAF mutations were, in most but not all the cases, concordant with the dominant tumor. A discordant pattern of BRAF mutation was also found in about 50% of the cases in which multiple foci of different histopathological variants were present.
Conclusion. The heterogeneous distribution of BRAF mutations suggests that discrete tumor foci in multifocal PTC may arise as independent tumors. This information has to be taken into account in the design of targeted therapeutic approaches with BRAF pathway inhibitors.
This article has been cited by other articles:
 |
|
 |
|
  R. Elisei, C. Ugolini, D. Viola, C. Lupi, A. Biagini, R. Giannini, C. Romei, P. Miccoli, A. Pinchera, and F. Basolo BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3943 - 3949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Antonelli, S. M. Ferrari, P. Fallahi, P. Berti, G. Materazzi, I. Marchetti, C. Ugolini, F. Basolo, P. Miccoli, and E. Ferrannini Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration Eur. J. Endocrinol., September 1, 2008; 159(3): 283 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Frasca, C Nucera, G Pellegriti, P Gangemi, M Attard, M Stella, M Loda, V Vella, C Giordano, F Trimarchi, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer Endocr. Relat. Cancer, March 1, 2008; 15(1): 191 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Xing BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications Endocr. Rev., December 1, 2007; 28(7): 742 - 762. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
